Koers Threshold Pharmaceuticals, Inc. Nasdaq
Aandelen
US8858072064
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 12,7 mln. 11,72 mln. | Omzet 2025 * | 1,37 mln. 1,26 mln. | Marktkapitalisatie | 8,95 mln. 8,26 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -22 mln. -20,29 mln. | Nettowinst (verlies) 2025 * | -34 mln. -31,36 mln. | EV/omzet 2024 * | 0,7 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 6,55 x |
K/w-verhouding 2024 * |
-0,42
x | K/w-verhouding 2025 * |
-0,35
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,04% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Eric Poma
CEO | Chief Executive Officer | 52 | 01-01-00 |
Jason Kim
PSD | President | 49 | 01-01-10 |
Kristen Quigley
COO | Chief Operating Officer | 53 | 01-01-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Eric Poma
CEO | Chief Executive Officer | 52 | 01-01-00 |
Harold Selick
CHM | Chairman | 69 | 01-08-17 |
David Hoffmann
BRD | Director/Board Member | 79 | 01-08-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+10,10% | 114 mld. | |
+12,84% | 107 mld. | |
-5,64% | 22,22 mld. | |
-0,67% | 21,28 mld. | |
-4,64% | 18,8 mld. | |
-6,58% | 17,51 mld. | |
-39,36% | 17,17 mld. | |
+6,98% | 14,14 mld. | |
+34,54% | 12,2 mld. |